Summary
We have reviewed recent progress in clinical as well as molecular aspects of familial Parkinson's disease (PD). Three genes have been identified as causes for different forms of familial PD or parkinsonism, i.e., alpha-synuclein, parkin, and tau. In addition, 9 other chromosome loci were identified to be linked to familial PD or dystoniaparkinsonism.
Alpha-synuclein mutations cause autosomal dominant levodopa-responsive PD. Parkin mutations cause autosomal recessive young onset familial PD. Tau gene mutations cause familial frontotemporal dementia and parkinsonism linked to chromosome 17. Mutated alpha-synucleins showed an increased tendency for self aggregation into an anti-parallel beta-sheet structure. Parkin protein appears to be essential for the survival of pigmented nuclei of the brain stem. Tau protein is an important microtubule-associated protein. Elucidation of the molecular mechanism of nigral neuronal death due to these mutations will contribute to a better understanding of familial as well as sporadic PD.
biochemical changes taking place within degenerating neurons have been elucidated [see ref . 3] . The interaction of genetic predisposition and nigral neurotoxins is believed to initiate the degenerative process within the nigral neurons in Parkinson's disease; and, as a result, mitochondrial respiratory failure [4] [5] [6] and oxidative stress [7] [8] [9] are induced within nigral neurons. Eventually neurons may die of apoptosis [10, 11] , but the question as to whether or not nigral neurons die of apoptosis has been debated for a long time.
The majority of PD patients are sporadic, but PD can be seen as a familial disorder of either autosomal dominant or autosomal recessive inheritance. Recently, two genes responsible for familial PD have been identified [12, 13] , and the molecular mechanism of nigral degeneration is being investigated. We review recent progress in the clinical and molecular aspects of familial PD in this communication.
Clinical Features and Chromosome Locations of Familial Parkinsonism
Many different clinical forms of familial PD and parkinsonism plus syndrome are known, among which eight chromosome loci have been found to be linked to different forms of familial PD or parkinsonism (Table 1) .
The clinical features of familial PD linked to the short arm of chromosome 2 consist of typical parkinsonian features, i.e., resting tremor, cogwheel rigidity, bradykinesia, and postural instability [14, 15] . The age of onset is variable between 36 and 89 years (mean, 58.5). In some families, dementia is a part of the clinical features. What is interesting in this form is its low penetrance, i.e., 40% [14, 15] . Therefore, other genetic backgrounds may determine the development of the disease. Elucidation of the molecular mechanism of failure to develop the disease appears to be important for the future neuroprotective treatment of PD.
In the short arm of chromosome 4, two loci close to each other have been found to be linked to different forms of PD [16, 17] . One of them is called Spellman-Muenter-Waters and Miller family (or simply Iowanian family) [18] [19] [20] [21] . Clinical features consist of levodopa-responsive parkinsonism with early development of dementia [18] [19] [20] [21] . Pathologically, Lewy bodies are found not only in the substantia nigra, but also in the cortical neurons [21] . Therefore, this form simulates familial diffuse Lewy body disease. What is interesting in this family is the presence of two different clinical phenotypes within the same family; one form is parkinsonism and the other is essential tremor. Although the molecular cloning of the disease gene has not been successful yet, the two phenotypes have the same haplotype in linkage analysis [16] . The other clinical form linked to the short arm of chromosome 4 presents levodopa-responsive parkinsonism [17] . To date only one family has been reported [17] , but there was no autopsy report in this family. The mode of inheritance appears to be autosomal dominant; however, father of the patients was spared and autosomal recessive inheritance cannot entirely be excluded. Clinical features of familial PD linked to the long arm of chromosome 4 consist of early onset levodopa-responsive parkinsonism [22, 23] . The average age of onset in the Contursi family reported by Golbe et al. [22] was 45.6 years; the initial symptoms were variable, including resting tremor, bradykinesia, or gait disturbance. They responded to levodopa well, but the average duration of the illness (9.2+4.9 years) was shorter than that of sporadic PD. Dementia was not uncommon in this family. Pathologically, the substantia nigra and the locus coeruleus showed neuronal degeneration, gliosis, and Lewy body formation; some cortical Lewy bodies were also seen [22] . The disease gene has been identified to be mutations of the alpha-synuclein gene [12] , which has been mapped to the long arm of chromosome 4 at 4g21 [24]. To date, two types of mutations have been reported. The G209A (Ala53Thr) mutation was the first mutation found, in families of Greek and Italian descent [12] . Later on a C88G (Ala30Pro) mutation was found in a German family [25] . The age of onset is earlier in the former mutation.
Clinical features of chromosome 6-linked familial PD consist of early-onset levodopa-responsive parkinsonism. The age of onset is usually between 20 and 30 years [26], but it ranges from 8 years to 58 years. Transient improvement in parkinsonism after a nap or sleep is common, and this phenomenon has been called diurnal fluctuation. In contrast to the tremor of late-onset PD, gait disturbance is more common as the presenting symptom. Dystonic features in the feet are not uncommon, and the initial symptom may be dystonic gait disturbance. Pathologically, this form is characterized by selective degeneration of the substantia nigra and the locus coeruleus. What is interesting in this form is the complete absence of Lewy bodies [27, 28] . Molecular analysis on why Lewy bodies are absent in this form appears to be important to explore the mechanism of Lewy body formation in sporadic PD and other forms of familial PD. The disease gene for this form has been identified as parkin [13] . telomeric region of the long arm of chromosome 6 [30] . The clinical features of this family were essentially the same as those of families reported by Yamamura et al. [31] , i.e., autosomal recessive early-onset parkinsonism with diurnal fluctuation. We thought this form might be linked to the Mn SOD gene. We did linkage analysis using microsatellite markers, which covered the Mn SOD gene region, with the collaboration with Professor Tsuji's group at Niigata University; and we were able to map the disease gene locus to 6g25.2-27. While we were doing linkage analysis on an another group of families with this form [32] , we found a patient who showed homozygous absence of a microsatellite marker in this region, i.e., D6S305 [33] , which gave the highest lod score in the linkage analysis. We thought that this marker might be located within the disease gene itself.
Then we collaborated with Professor Shimizu's group at Keio University School of Medicine; his group has constructed a comprehensive library of human genomic DNA, i.e., Keio BAC library [34] . We screened the Keio BAG library with D6S305, and eventually we were able to clone a cDNA consisting of 2,690 bp, of which 1,395 by were the coding region [13] . We named this novel gene parkin. The profile of the parkin gene is shown in Table 2 . What is interesting to us is the presence of partial homology to ubiquitin in the N-terminus and a RING-fingerlike structure in the C-terminal region. The implication of these structures will be discussed later.
Mutational Analysis o , f Parkin Gene
We have analyzed more than 50 families with autosomal recessive early-onset PD (AR-JP) and found many kinds of different mutations in the parkin gene. Deletional mutations were much more frequent than point mutations. Representative mutations are shown in Fig. 1 [35] . There is a mutational hot spot between exon 3 and 6, and the deletion of exon 4 appears to be the most common. There is no clear correlation between the site of mutation and clinical features. But there is a tendency that patients with exon 4 deletion tend to show earlier onset of the disease.
Homozygous deletional mutations can be detected by conventional PCR analysis of genomic DNA. But once in a while even when patients do not show a homozygous deletional mutation of parkin gene, the clinical features are compatible with AR-JP. We believe that some of them are compound heterozygotes of parkin gene mutations, in which there are two different mutations in the parkin genes. Such mutations cannot be detected by conventional PCR. We are developing methods to detect such compound heterozygotes by quantitative PCR.
Although the majority of patients show deletional mutations, some have a point mutation in parkin gene. Western patients tend to show a higher incidence of point mutations [36] .
Molecular Biology of the Parkin Protein
To explore the function of parkin protein and the molecular mechanism of neuronal degeneration in the parkin-defective familial PD, we raised an antibody against parkin protein and did immunoblotting and immunostaining study on normal as well as PD brains [37] . First of all, parkin mRNA was ubiquitously expressed in many areas of the brain as well as systemic organs [13] . However, parkin protein was expressed in the nigral striatal system more abundantly than in other brain areas. Expression of parkin protein was normal in sporadic PD patients. The striatum showed a high amount of immunoreactive parkin protein, indicating that the protein exists in the nerve terminal areas as well as in neuronal cell bodies, which means that parkin protein is transported to the terminal area by axonal transport.
Parkin protein was completely absent in an AR-JP patient with an exon 4 deletion [37] . None of the brain areas studied showed immunoreactive parkin protein. But the neuronal degeneration was restricted to the substantia nigra and the locus coeruleus, indicating that parkin protein is essential for the survival of the latter two nuclei. We also confirmed the absence of parkin protein in AR-JP by immunoblotting [37] . Then we conducted a cell fraction study using frontal lobes of control patients and analyzed the fractions by immunoblotting. Parkin protein was present in the supernatant and the Golgi fraction [37] , suggesting that parkin protein passes through the Golgi apparatus before going to its final destination.
The presence of a ubiquitin-like structure in the parkin gene is an important clue to investigate the function of the parkin protein. Ubiquitin plays an important role in protein processing and degradation in the proteasome. Parkin protein may act as a ubiquitin-like protein or it may be incorporated in ubiquitin pathways. The RING-finger-like structure is another important key to understand the function of parkin protein. Proteins with a RING-finger structure can interact with other proteins and nucleic acids.
Molecular Biology of Alpha-Synuclein
The alpha-Synuclein gene was cloned by the screening of a cDNA library of Torpedo electric organ [38] . Alpha-Synuclein is a brain-specific protein expressed in the presynaptic membranes and the nucleus [39], and it is widely expressed in the brain. However, it is more abundant in the cortical areas and basal ganglia [39] . The alpha-synuclein gene has been mapped to 4q 21-22 [24, 40] . Alphasynuclein is the same as NACP (non-amyloid component precursor) [41, 42] , NAC is deposited in the amyloid plaques of Alzheimer's disease. It is interesting to note that normal alpha-synuclein is heavily deposited in the Lewy bodies of sporadic Parkinson's disease [43, 44] ; furthermore, alpha-synuclein is deposited also in the cytoplasm and neuronal processes. Thus alpha-synuclein appears to be a protein that tends to aggregate when the cellular milieu has deviated from normal. For instance, oxidative stress can induce aggregation of alpha-synuclein El Agnaf et al [46] reported that when the wild type or mutant types of alpha-synuclein were expressed in a neuroblastoma cell line, apoptosis was induced by formation of beta-sheet and amyloid-like filaments. Conway et al. [47] reported that A53T-mutated alpha-synuclein showed accelerated fibril formation when incubated in vitro compared with the wild-type alpha-synuclein. Giasson et al. [48] reported that both wild-type and two mutant alpha-synucleins selfaggregated and assembled into 10-19-nm-wide filaments in vitro and that the ultrastructure of these filaments resembled the major ultrastructural elements of authentic Lewy bodies. Narhi et al. [49] showed that both familial PD mutations of alpha-synuclein accelerated the aggregation. They showed that both wild-type and mutant alpha-synuclein formed insoluble fibrillar aggregates with an antiparallel beta-sheet structure upon incubation at physiological temperature in vitro. Aggregate formation was accelerated by both PD-linked mutations; and the lag time under their experimental conditions for the formation of precipitable aggre-gates was about 280 h for the wild-type protein, 180 h for the A30P mutant, and only 100 h for the A53T mutant protein.
Engelender et al.
[50] found a novel protein that interacts with alphasynuclein, and named it synphilin-l. Co-transfection of HEK 293 cells with alpha-synuclein and synphilin-1 yielded cytoplasmic eosinophilic inclusions similar to Lewy bodies.
Jensen et al. [51] reported the N-terminal region of alpha-synuclein to be essential for the binding of alpha-synuclein to fast axonal transport vesicles. The A30P mutation is located in this binding domain, and the mutation was reported to disrupt vesicular binding function. Jensen et al. [52] reported that alphasynuclein binds to tau and stimulates the protein kinase A-catalyzed phosphorylation of serine residues 262 and 356 of tau. Tau is a microtubule-binding protein, mutations of which cause frontotemporal dementia and parkinsonism linked to chromosome 17, as will be discussed next.
Thus alpha-synuclein appears to play an important role in nigral neurodegeneration in PD. Not only mutated forms but also the wild type of alphasynuclein appears to be one of the key proteins in neurodegeneration because of its molecular nature for self aggregation and beta-sheet formation. Of further interest, alpha-synuclein aggregates were found in multiple system atrophy [53], Lewy body dementia [54-56], Alzheimer's disease [57] , Down's syndrome [58] , Hallervorden-Spatz disease [59] , and amyotrophic lateral sclerosis [60] .
It is important to note that all three proteins that induce familial parkinsonism, i.e., alpha-synuclein, parkin, and tau, are related to axonal transport.
Familial Frontotemporal Dementia Linked to Chromosome 17
Familial frontotemporal dementia is an autosomal dominant familial disorder manifesting progressive dementia of the non-Alzheimer type, such as aphasia, impairment of set shifting, memory loss, disorientation, echolalia, perseveration, hallucinations, and delusions. Behavioral changes such as disinhibition, aggressiveness, poor impulse control, violence, alcoholism, hyperorality, and neglect of personal hygiene are also frequent. Motor disturbance consists of parkinsonism and amyotrophy in some patients. Clinical features of this entity were first described by Wszolek et al. [61] in 1992 as autosomal dominant parkinsonism and dementia with pallido-ponto-nigral degeneration, and then by Lynch et al. [62] in 1994 as chromosome 17-linked disinhibition-dementiaparkinsonism-amyotrophy complex. This entity has been called by many different names, including familial progressive subcortical gliosis; but after the consensus meeting in 1996, the name of this entity has been restricted to frontotemporal dementia and parkinsonism (FTDP) linked to chromosome 17 [63] . MRI shows frontotemporal atrophy, and a marked reduction in cerebral blood flow is detectable in the frontotemporal region by SPECT [64] .
Pathologic features consist of frontotemporal atrophy with neuronal loss and gliosis involving the frontotemporal cortex, substantia nigra, locus coeruleus, pontine tegmentum, globus pallidus, subthalamic nucleus, pyramidal tracts, and cerebral cortex [62, 65, 66] . No Lewy bodies are seen. The pathologic hallmark is the widespread appearance of tau-positive neurons and astrocytes. Ballooned neurons with tau-positive neuronal inclusions are seen in affected areas [65, 66] , but not always. Neuropil threads and astrocytic plaques similar to those seen in corticobasal degeneration are reported in some cases [67] . In addition, numerous neurofibrillary tangles with an unusual morphology and distribution are reported in some cases. Ring-shaped neurofibrillary tangles (NFTs) partially surrounding the nucleus were reported in frontal, temporal, insular, and postcentral cortices, as well as in dentate gyrus without senile plaque formation in one family with a Ser305Asn mutation in the tau gene [68] .
The tau gene is localized in the long arm of chromosome 17 at 17q 21-22 [69] , and mutations of this gene cause clinical phenotypes of frontotemporal dementia and parkinsonism linked to chromosome 17 [69] [70] [71] [72] . To date 6 exonic mutations and 4 intronic mutations are known. Exonic mutations involve exon 9 (G1y272Val) [71] , exon 10 (Pro301 Leu, Asn279Lys, and Ser305Asn) [68-7l] , exon 12 (Va1337Met) [69] , and exon 13 (Arg406Try) [70] ; intronic mutations involve the proximity of the Y-splice-site to exon 10, consisting of point mutations [71, 72] . Usually exon 10 is spliced out by alternating splicing; but in the presence of the intronic mutations, exon 10 has a higher chance being incorporated into the transcript.
Tau is a microtubule-associated protein normally localized in axons [73] , and is a major component of the paired helical filaments that accumulate in the neurofibrillary tangles of Alzheimer's disease [74] . Tau promotes microtubule assembly, and mutated tau proteins are said to show reduced ability to promote it [75] . The Pro301Leu mutation in exon 10 involves the second microtubule binding domain of tau protein, and the disruption of binding of tau to the microtubule is proposed to be a key event in the pathogenesis of FTDP [76] . In the case of an intronic mutation involving the intron after exon 10 at +16, Goedert et al. [77] reported that the mutation destabilizes a predicted stem-loop structure and leads to an over-representation of the soluble four-repeat tau isoforms, which assemble into wide, twisted, ribbon-like filaments and ultimately result in abundant neuronal and glial tau pathology. Intronic mutations lead to an abnormal preponderance of four-repeat tau isoforms, and exonic mutations lead to a marked reduction in the ability of tau to promote microtubule assembly [78] .
Not all cases of familial frontotemporal dementia and parkinsonism are linked to chromosome 17. In more than half of such families, the chromosome locus is unknown [75, 79] . Recently, a chromosome 3-linked familial form of dementia was reported [80, 81] . In one autopsied case, the brain showed betaA4amyloid-containing neuritic plaques without neurofibrillary tangles; and the tissue was negative for tau accumulation [81] .
X -Linked Dystonia Parkinsonism (Lubag Dystonia, DYT3)
X-linked dystonia-parkinsonism is a severe, adult-onset disorder with a mean onset at 35 + 8.0 years of age (range, 12-48) [82] . The initial symptom is usually dystonia such as blepharospasm, oromandibular dystonia, or dystonia involving trunk and/or limbs. Later on the dystonia becomes generalized. Parkinsonism was reported in 36% of cases in one large series [82] , and consisted of tremor, rigidity, bradykinesia, and postural instability. An autopsy study was reported in one of the Filipino patients. The principal neuropathologic findings were neuronal loss and a multifocal mosaic pattern of astrocytosis restricted to the caudate and lateral putamen [83] . The substantia nigra and the locus coeruleus were unremarkable.
Lubag dystonia was originally found in the Philippine island of Panay. The disease locus has been assigned to the proximal long arm of the X-chromosome by linkage analysis [84, 85] and the more precisely to Xq-q 13 by the analysis of allelic association [86, 87] . Hashimoto, M., Hsu, L.J., Xia, Y., Takeda, A., Sisk, A., Sundsmo, M., and Masliah, E. 
